StockNews.AI
CODX
StockNews.AI
112 days

Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

1. Co-Diagnostics will release Q1 2025 financial results on May 8. 2. A conference call to discuss results is scheduled for the same day at 4:30 p.m. 3. CODX utilizes proprietary technology for molecular diagnostic tests. 4. The call will have key executives discussing company performance. 5. Webcast available for those unable to join the live call.

Earnings
-2.99%Current Return
VS
-0.04%S&P 500
$0.371104/29 07:35 AM EDTEvent Start
$0.3604/30 02:33 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming Q1 results could indicate growth; past earnings have led to stock increases.

How important is it?

Quarterly financial results often drive short-term stock movements; potential investor reactions expected.

Why Short Term?

Results announcement on May 8 may cause immediate market reactions.

Related Companies

PCRNVTAEXAS
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagnostics.com on the Events & Webcasts page, or accessible directly here Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with participant passcode 1977478 If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website. About Co-Diagnostics, Inc. Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease. Investor Relations Contact: Andrew BensonHead of Investor Relations+1 801-438-1036investors@codiagnostics.com

Related News